Tigecycline: A Review of Properties, Applications, and Analytical Methods

Silva, Lucélia Magalhães da; Salgado, Hérida Regina Nunes

doi:10.1097/ftd.0b013e3181dda54f

Cited by 31 publications

(26 citation statements)

References 53 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Tigecycline is a new tetracycline derivate and its chemical structure also contains phenolic β-diketone. 22 Study in animals showed that tigecycline reduced the MMP-9 levels; 10 however, result of the present study is not inline. Neither at the first nor at the seventh day after administration showed significant differences between the two groups.…”

Section: Discussioncontrasting

confidence: 54%

MMP-9, brain edema, and length of hospital stay of patients with spontaneous supratentorial intracerebral hemorrhage after hematoma evacuation along with the administration of tigecycline

et al. 2017

View full text Add to dashboard Cite

ABSTRAKHasil: Didapatkan perbedaan tidak bermakna pada proporsi subjek yang mengalami penurunan kadar MMP-9 pada hari pertama (48% vs 50%; p=0,902;OR=1,(1)(2)(3)(4)(5)(6)(7) p=0,296;OR=1,9); proporsi pengurangan edema serebri (68% vs 80%; p=0,58); LOS (median 12 hari vs 13 hari p=0,256; proporsi subjek dengan LOS ≥15 hari 40% vs 27% p=0,243;OR=1,81; NNT=8).Kesimpulan: Pada pasien PISS yang dilakukan evakuasi hematoma, tigesiklin tidak menurunkan kadar MMP-9 dan derajat edema serebri, serta tidak memperpendek LOS. ABSTRACT Background:The high plasma level of matrix metalloproteinses-9 (MMP-9) is believed to disrupt the bloodbrain barrier (BBB) and cause brain edema, as well as increase patient's length of hospital stay (LOS). Tigecycline showed ability to reduce the MMP-9 level on study in animals. This study aimed to evaluate whether tigecycline can reduce the plasma levels of MMP-9; brain edema; and LOS of patients with supratentorial spontaneous intracerebral hemorrhage (SSICH).

show abstract

Section: Discussioncontrasting

confidence: 54%

MMP-9, brain edema, and length of hospital stay of patients with spontaneous supratentorial intracerebral hemorrhage after hematoma evacuation along with the administration of tigecycline

et al. 2017

View full text Add to dashboard Cite

show abstract

“…8 Gastrointestinal adverse effects have been described as prevalent: nausea and vomiting were the first (30%) and second (20%) most common events, respectively. Other much less common adverse events included headache, hypertension, anemia, prolonged activated partial thromboplastin time and prothrombin time, increased aspartate aminotransferase and alanine aminotransferase, dizziness, insomnia, pruritus, and rash.…”

Section: Discussionmentioning

confidence: 99%

Neutrophils Engraftment Delay During Tigecycline Treatment in 2 Bone Marrow–transplanted Patients

Maximova

Zanon

Verzegnassi

et al. 2013

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…Tigecycline, to date, the only commercially available glycylcycline, is structurally derived from minocycline by adding a side chain to the carbon ring of the tetracycline backbone, yielding an extended antimicrobial spectrum (21). How this modification preserves the anti-inflammatory properties is not completely explored.…”

Section: Previous Studiesmentioning

confidence: 99%

Effects of Tigecycline and Doxycycline on Inflammation and Hemodynamics in Porcine Endotoxemia

Seth¹,

Sjölin²,

Larsson³

et al. 2015

Shock

View full text Add to dashboard Cite

Antibiotics might, apart from an antimicrobial effect, also exert anti-inflammatory effects. The novel antibiotic tigecycline, potentially useful in septic shock from gram-negative multiresistant bacteria, is structurally related to antibiotics with known anti-inflammatory properties. However, its anti-inflammatory effects have not been previously explored in vivo. Using a sterile integrative porcine sepsis model, we investigated the anti-inflammatory and circulatory effects of tigecycline in comparison with doxycycline and placebo. Eighteen pigs were randomized to receive tigecycline 100 mg, doxycycline 200 mg, or placebo and subjected to 6-h endotoxin infusion at 0.5 μg kg(-1) h(-1). Markers of inflammation, nitric oxide production, vascular permeability, hemodynamics, organ dysfunction, tissue metabolism, and acid-base parameters were monitored. Peak plasma tumor necrosis factor-α was lower in the doxycycline group (P = 0.031) but not in the tigecycline group (P = 0.86) compared with placebo, with geometric mean plasma concentrations of 16, 79, and 63 ng mL(-1), respectively. Mean arterial pressure was higher 4 to 6 h in the tigecycline group, with values at 6 h of 107 ± 9 mmHg compared with the placebo and doxycycline groups (85 ± 27 mmHg and 90 ± 32 mmHg, respectively; P = 0.025). The white blood cell and the neutrophil granulocyte counts were less reduced in the doxycycline group but not in the tigecycline group at 4 to 6 h (P = 0.009 and P = 0.019, respectively). Other markers of inflammation, organ dysfunction, tissue metabolism, and acid-base parameters were unaffected by tigecycline. Consistent with known anti-inflammatory properties, doxycycline yielded decreased tumor necrosis factor-α levels. Tigecycline did not affect cytokine levels but counteracted hypotension and hypoperfusion.

show abstract

Tigecycline: A Review of Properties, Applications, and Analytical Methods

Cited by 31 publications

References 53 publications

MMP-9, brain edema, and length of hospital stay of patients with spontaneous supratentorial intracerebral hemorrhage after hematoma evacuation along with the administration of tigecycline

MMP-9, brain edema, and length of hospital stay of patients with spontaneous supratentorial intracerebral hemorrhage after hematoma evacuation along with the administration of tigecycline

Neutrophils Engraftment Delay During Tigecycline Treatment in 2 Bone Marrow–transplanted Patients

Effects of Tigecycline and Doxycycline on Inflammation and Hemodynamics in Porcine Endotoxemia

Contact Info

Product

Resources

About